Misplaced Pages

Dapagliflozin/sitagliptin, sold under the brand name Sidapvia, is a fixed-dose combination anti-diabetic medication used for the treatment of type 2 diabetes. It contains dapagliflozin, as propanediol monohydrate, a SGLT-2 inhibitor; and sitagliptin, as phosphate monohydrate, a DPP-4 inhibitor. It is taken by mouth.

References

1. ^ "TGA eBS - Product and Consumer Medicine Information Licence". Archived from the original on 8 July 2024. Retrieved 8 July 2024.
2. "Sidapvia (AstraZeneca Pty Ltd)". Therapeutic Goods Administration (TGA). 1 July 2024. Archived from the original on 7 July 2024. Retrieved 8 July 2024.
3. "Sidapvia 10/100 dapagliflozin 10 mg (as propanediol monohydrate)/sitagliptin 100 mg (as phosphate monohydrate) film coated tablets blister pack (405540)". Therapeutic Goods Administration (TGA). 8 June 2024. Archived from the original on 8 July 2024. Retrieved 8 July 2024.
4. Dunleavy K (24 July 2023). "AstraZeneca enlists SK Chemicals to produce diabetes combo drug Sidapvia". Fierce Pharma. Retrieved 8 July 2024.

• Medicine

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Dipeptidyl peptidase-4 inhibitors
• Drugs developed by AstraZeneca
• Combination diabetes drugs
• SGLT2 inhibitors
• Pharmacology stubs